From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2017 call → NOWe need to determine if management describes a recent crossing from candidate to approved/specified/listed/qualified status inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is ahead. Scan transcript for keywords: approved, specified, listed, qualified, registered, reimbursed, pre-authorized, supplier list, procurement, specification, reference design, etc. Management discusses design wins, ramps, shipments. For example, "commenced production shipments", "volume production shipments", "design win for G.Now last mile access at a major telco operator in Asia, which will ramp to revenues in the second half of 2018." That's a design win, but not necessarily a listing in a procurement system. They talk about "initial volume production ramp of DOCSIS 3.1 platforms for a major US cable operator." That's a customer win, but not a systemic access. They mention "we have broadened our operating engagements for last mile access" and "commenced shipments" but no mention of being added to an approved vendor list, being specified in a standard, etc. They mention "we are at the early stages of new platform growth drivers in the form of force-touch solution to the smartphones and power modules into Tier 1 Intel Purley base servers." That's early stages, but not a systemic access. They mention "we have received customer validation of the superiority of the integration levels expected performance and time to market advantages" for 400G PAM-4, but that's sampling. No mention of being qualified onto a roster, being written into specifications, being added to a formulary, etc. The closest is "design win" but that's a standard customer win where each order still must be individually persuaded? Actually design win means the product is designed into a platform, which could be a form of specification. But the question asks about "approved, specified, listed, qualified, registered, reimbursed, or pre-authorized choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems" so that future business can arrive without a discrete selling event. A design win is often a specification, but the transcript doesn't explicitly describe that as a systemic access.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.